The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that affects red blood cells, causing symptoms like dark urine, ...

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s ...

EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 77,700 shares, a ...

We came across a bullish thesis on KORU Medical Systems, Inc. (KRMD) on Substack by Shareholdersunite. In this article, we ...

Mizhou Securities analyst Graig Suvannavejh commented, "APLS reported 4Q results this AM. With 4Q Syfovre sales already preannounced, for 1Q25, mgmt called out likely Syfovre softness, due to ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or argenx SE is a better investment based on AAII's A+ Investor grades ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...